Dr. Timothy Kuzel
Add to your Care-Team
Dr. Timothy Kuzel
Dr. Timothy Kuzel
Internal Medicine - Oncology
I specialize in
Internal Medicine - Oncology
Internal Medicine - Hematology
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
675 N St Clair Ste 14-100
Chicago , IL 60611
Accepted Insurance Plans
Coventry Health Care
I was educated and trained at
Medical / Graduate School
University of Michigan Medical School
Dr. Timothy Kuzel M
I've won the following awards
Top Doctor, Chicago Magazine
Outcome of Patients Treated With a Single-Fraction Dose of Palliative Radiation for Cutaneous T-Cell Lymphoma.
Int. J. Radiat. Oncol. Biol. Phys., Jul (2012)
J Natl Compr Canc Netw., Apr;10(4):502-35 (2012)
Cutaneous T-cell lymphomas: a review of new discoveries and treatments.
Curr Treat Options Oncol., Mar;13(1):102-21 (2012)
J Natl Compr Canc Netw., Sep;9(9):960-77 (2011)
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with Oâ¶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Clin. Cancer Res., Sep;17(17):5748-54 (2011)
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Leuk. Lymphoma., Aug;52(8):1474-80 (2011)
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
N. Engl. J. Med., Jun;364(22):2119-27 (2011)
Merkel cell carcinoma metastatic to the small bowel mesentery.
Rare Tumors., 3(1):e2 (2011)
In situ photoimmunotherapy: a surgery- and limb-sparing approach to the treatment of cutaneous metastases in advanced melanoma.
Arch Dermatol., Aug;146(8):831-4 (2010)
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
J. Immunother., Sep;33(7):716-22 (2010)
Cutaneous involvement with marginal zone lymphoma.
J. Am. Acad. Dermatol., Jul;63(1):142-5 (2010)
Effect of sunitinib on renal cell carcinoma cutaneous metastasis.
Int. J. Dermatol., Nov;48(11):1269-70 (2009)
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Leuk. Lymphoma., Dec;50(12):1969-76 (2009)
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
J. Clin. Oncol., Sep;27(26):4398-405 (2009)
NCCN clinical practice guidelines in oncology: kidney cancer.
J Natl Compr Canc Netw., Jun;7(6):618-30 (2009)
NCCN clinical practice guidelines in oncology: testicular cancer.
J Natl Compr Canc Netw., Jun;7(6):672-93 (2009)
A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
J Pain Symptom Manage., Aug;38(2):291-8 (2009)
J Natl Compr Canc Netw., Jan;7(1):8-39 (2009)
Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and SÃ©zary syndrome in primary cutaneous marginal zone lymphoma.
J. Am. Acad. Dermatol., Aug;59(2):245-54 (2008)
NCCN Task Force Report: Oral chemotherapy.
J Natl Compr Canc Netw., Mar;6 Suppl 3:S1-14 (2008)
Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor.
Urology., Feb;73(2):444.e11-2 (2009)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA., Feb;299(8):914-24 (2008)
The usefulness of CD26 in flow cytometric analysis of peripheral blood in SÃ©zary syndrome.
Am. J. Clin. Pathol., Jan;129(1):146-56 (2008)
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
Leuk. Lymphoma., Dec;48(12):2397-402 (2007)
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
J. Clin. Oncol., Jul;25(21):3109-15 (2007)
Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Oncology (Williston Park, N.Y.)., May;21(6):689-96; discussion 699-700, (2007)
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Arch. Intern. Med., May;167(10):1041-9 (2007)
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and SÃ©zary syndrome.
J. Am. Acad. Dermatol., Apr;56(4):580-3 (2007)
Kidney cancer. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw., Nov;4(10):1072-81 (2006)
Testicular cancer. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw., Nov;4(10):1038-58 (2006)
Bladder cancer. Clinical guidelines in oncology.
J Natl Compr Canc Netw., Nov;4(10):984-1014 (2006)
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Br. J. Haematol., Dec;135(5):642-50 (2006)
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
J. Am. Acad. Dermatol., Nov;55(5):807-13 (2006)
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leuk. Res., May;31(5):599-604 (2007)
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
J. Invest. Dermatol., Jul;126(7):1641-7 (2006)
Bexarotene in the treatment of cutaneous T-cell lymphoma.
Expert Opin Pharmacother., May;7(7):907-15 (2006)
Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.
Cancer., May;106(9):2051-7 (2006)
Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience.
Med. Oncol., 22(4):399-405 (2005)
Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
Cancer Treat. Res., 126:263-87 (2005)
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna.
Clin. Cancer Res., Sep;11(17):6218-25 (2005)
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
Blood., Nov;106(10):3343-7 (2005)
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy.
Curr. Opin. Hematol., Jul;12(4):273-8 (2005)
The Research on Adverse Drug Events and Reports (RADAR) project.
JAMA., May;293(17):2131-40 (2005)
Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Arch Dermatol., Mar;141(3):305-11 (2005)
Denileukin diftitox: a concise clinical review.
Expert Rev Anticancer Ther., Feb;5(1):33-8 (2005)
A review of recent findings involving interleukin-2-based cancer therapy.
Curr Opin Oncol., Nov;16(6):542-6 (2004)
Kidney cancer. Clinical practice guidelines.
J Natl Compr Canc Netw., Jan;3(1):84-93 (2005)
Testicular cancer. Clinical practice guidelines.
J Natl Compr Canc Netw., Jan;3(1):52-76 (2005)
Bladder cancer. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw., Jan;3(1):4-5, 19-34 (2005)
Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept.
Arch Dermatol., Dec;140(12):1539-40 (2004)
Pure red-cell aplasia and epoetin therapy.
N. Engl. J. Med., Sep;351(14):1403-8 (2004)
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients.
Cancer., Sep;101(5):957-62 (2004)
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
J. Am. Acad. Dermatol., Jul;51(1):25-32 (2004)
Cutaneous T-cell lymphoma: a paradigm for biological therapies.
Leuk. Lymphoma., Sep;45(9):1755-65 (2004)
Agreement between prostate cancer patients and their clinicians about utilities and attribute importance.
Health Expect., Jun;7(2):115-25 (2004)
High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma.
Hematol. Oncol. Clin. North Am., Dec;17(6):1475-83, xi (2003)
Novel agents for cutaneous T-cell lymphoma.
Hematol. Oncol. Clin. North Am., Dec;17(6):1459-66, x (2003)
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
Hematol. Oncol. Clin. North Am., Dec;17(6):1435-48, ix (2003)
Systemic chemotherapy for the treatment of mycosis fungoides and SÃ©zary syndrome.
Dermatol Ther., 16(4):355-61 (2003)
Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
Semin Cutan Med Surg., Sep;22(3):150-61 (2003)
Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Exp. Hematol., Oct;31(10):903-10 (2003)
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect.
Bone Marrow Transplant., Jan;25(1):111-3 (2000)
Novel treatment approaches for cutaneous T-cell lymphoma.
Cancer Treat. Res., 99:227-40 (1999)
Angiosarcoma of the bladder: a review.
Urology., Nov;52(5):778-84 (1998)
Metastatic bladder cancer: advances in treatment.
Eur. J. Cancer., Jan;33 Suppl 1:S23-6 (1997)
Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
Blood., Feb;87(3):906-11 (1996)
Neurologic complications of patients with small cell prostate carcinoma. Report of two cases.
Cancer., Dec;74(12):3159-63 (1994)
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
Cancer., Sep;72(6):1965-8 (1993)
Cutaneous T-cell lymphoma.
Oncol Nurs Forum., Jul;18(5):901-8 (1991)
Monoclonal antibody therapy of lymphoproliferative disorders.
Oncology (Williston Park, N.Y.)., Mar;4(3):77-84; discussion 84, 89-90, 92-3 (1990)
Dr. Timothy Kuzel M